These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 9861222)

  • 21. Decisions on women's health: menopause and hormone replacement therapy.
    Visser A
    Patient Educ Couns; 2004 May; 53(2):119. PubMed ID: 15140449
    [No Abstract]   [Full Text] [Related]  

  • 22. The impact of media attention, family history, politics and maturation on women's decisions regarding hormone replacement therapy.
    Andrist LC
    Health Care Women Int; 1998; 19(3):243-60. PubMed ID: 9601305
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combination therapy with hormone replacement and alendronate for prevention of bone loss in elderly women: a randomized controlled trial.
    Greenspan SL; Resnick NM; Parker RA
    JAMA; 2003 May; 289(19):2525-33. PubMed ID: 12759324
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Thyroid hormone use and bone mineral density in elderly women. Effects of estrogen.
    Schneider DL; Barrett-Connor EL; Morton DJ
    JAMA; 1994 Apr; 271(16):1245-9. PubMed ID: 7848399
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Patient willingness to take teriparatide.
    Fraenkel L; Gulanski B; Wittink D
    Patient Educ Couns; 2007 Feb; 65(2):237-44. PubMed ID: 16965888
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Osteoporosis management: physicians' recommendations and womens' compliance following osteoporosis testing.
    Cole RP; Palushock S; Haboubi A
    Women Health; 1999; 29(1):101-15. PubMed ID: 10427644
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Women's awareness and knowledge of hormone therapy post-Women's Health Initiative.
    Rigby AJ; Ma J; Stafford RS
    Menopause; 2007; 14(5):853-8. PubMed ID: 17429334
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Factors affecting long-term adherence to hormone replacement therapy after screening for osteoporosis.
    Steel SA; Albertazzi P; Howarth EM; Purdie DW
    Climacteric; 2003 Jun; 6(2):96-103. PubMed ID: 12841879
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial.
    Cauley JA; Robbins J; Chen Z; Cummings SR; Jackson RD; LaCroix AZ; LeBoff M; Lewis CE; McGowan J; Neuner J; Pettinger M; Stefanick ML; Wactawski-Wende J; Watts NB;
    JAMA; 2003 Oct; 290(13):1729-38. PubMed ID: 14519707
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Postmenopausal osteoporosis in women].
    Reginster JY; Devogelaer JP; Kaufman JM; Appelboom T; Vanhaelst L
    Rev Med Liege; 1999 Apr; 54(4):335-40. PubMed ID: 10389480
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Timing of follow-up densitometry in hormone replacement therapy users for optimal osteoporosis prevention.
    Checa MA; Del Rio L; Rosales J; Nogués X; Vila J; Carreras R
    Osteoporos Int; 2005 Aug; 16(8):937-42. PubMed ID: 15616756
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Initiation of hormone replacement therapy after diagnosis of osteoporosis by bone densitometry.
    Phillipov G; Mos E; Scinto S; Phillips PJ
    Osteoporos Int; 1997; 7(2):162-4. PubMed ID: 9166398
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Patterns of medication use before and after bone densitometry: factors associated with appropriate treatment.
    Solomon DH; Levin E; Helfgott SM
    J Rheumatol; 2000 Jun; 27(6):1496-500. PubMed ID: 10852277
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Perimenopausal women's views on taking hormone replacement therapy to prevent osteoporosis.
    Draper J; Roland M
    BMJ; 1990 Mar; 300(6727):786-8. PubMed ID: 2386562
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Postmenopausal osteoporosis].
    László A
    Orv Hetil; 2004 Jan; 145(1):3-13. PubMed ID: 15222134
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Structural model for osteoporosis preventing behavior in postmenopausal women.
    Estok PJ; Sedlak CA; Doheny MO; Hall R
    Nurs Res; 2007; 56(3):148-58. PubMed ID: 17495570
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of treatment intentions and concerns about side effects in women's decision to discontinue postmenopausal hormone therapy.
    Reynolds RF; Obermeyer CM; Walker AM; Guilbert D
    Maturitas; 2002 Nov; 43(3):183-94. PubMed ID: 12443835
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Peripheral bone densitometry: an old friend revisited.
    Kleerekoper M; Nelson DA
    Trans Am Clin Climatol Assoc; 1998; 109():62-70; discussion 70-2. PubMed ID: 9601128
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effectiveness of raloxifene on bone mineral density and serum lipid levels in post-menopausal women with low BMD after discontinuation of hormone replacement therapy.
    Song EK; Yeom JH; Shin HT; Kim SH; Shin WG; Oh JM
    J Clin Pharm Ther; 2006 Oct; 31(5):421-7. PubMed ID: 16958819
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Quantitative computerized tomographic densitometry for the evaluation of osteoporosis risk in menopausal women].
    Klejewski A; Tomaszewska K; Kostrzak W; Chojnicki A; Sajda M
    Ginekol Pol; 2005 Aug; 76(8):639-42. PubMed ID: 16363370
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.